Clozaril® Connect services and resources

Clozaril® Connect is a support programme to help clinicians diagnose, treat, and manage patients with treatment resistant schizophrenia (TRS) who may benefit from clozapine – the only treatment recommended by NICE for TRS. In addition to our CPMS offering, Clozaril® Connect provides exciting new initiatives to give you the best support in diagnosing, treating and managing treatment resistant schizophrenia patients.

Clozaril® Patient Monitoring Service (CPMS)

As part of Clozaril® Connect support programme, Viatris continues to offer the Clozaril® Patient Monitoring Service (CPMS). For more information about this, view the CPMS section.

Plasma Assay test

Viatris is partnering with Analytical Services International (ASI) to provide plasma serum testing for Clozaril® patients. From the new ASI Laboratory Portal (available now at asilab.co.uk), you can download request forms which can be customised as required for your local clozapine teams. Samples will continue to be collected in purple-topped blood tubes, and will be analysed within 48 hours of receipt. Registered users can view and print results via the Laboratory Portal,including historical results for monitoring trends. ASI will also offer expert interpretation and advice on results by phone upon request. A reduced cost per test has been negotiated with suppliers for trusts with Clozaril (Please liaise directly with ASI and Viapath to use this service).

Point of Care (POC) testing

As part of Viatris’s endeavour to improve access to clozapine for TRS patients, provision of a POC device will be no longer be linked to a minimum number of patients. If your trust can allocate resources, Viatris are very happy to provide a device on loan with training to support its functioning.

Patient Support Website

Partnership in Education

Viatris continually seek opportunities to provide educational support like live and on demand webinars, bespoke trainings etc for all our customers. Please subscribe to Viatris Connect for more details.

Partnering with Viatris

Clozapine is under-prescribed in the UK,1 so many patients with TRS are not being given the opportunity to make a real difference to their schizophrenia symptoms. By partnering with Viatris and engaging with the Clozaril® Connect programme, we can take positive action together to ensure the timely prescribing of Clozaril® as third-line treatment for schizophrenia, and improve the positive and negative symptoms of schizophrenia, social functioning, and the quality of life of your patients with TRS.

Reference

  1. National Audit of Schizophrenia (NAS). Second National Audit of Schizophrenia: What you need to know. The Royal College of Psychiatrists, 2014.

This website is owned and managed by Viatris.

This website is intended for UK and Ireland healthcare professionals only.

Clozaril is indicated in treatment-resistant schizophrenic patients and in schizophrenia patients who have severe, untreatable neurological adverse reactions to other antipsychotic agents, including atypical antipsychotics.

Treatment resistance is defined as a lack of satisfactory clinical improvement despite the use of adequate doses of at least two different antipsychotic agents, including an atypical antipsychotic agent, prescribed for adequate duration.

Clozaril is also indicated in psychotic disorders occurring during the course of Parkinson's disease, in cases where standard treatment has failed.

© Copyright 2023 Viatris Inc. All rights reserved.

Viatris UK Healthcare Limited (company registration number 09189103), an English company with a registered office address at 20 Station Close, Potters Bar, Hertfordshire, EN6 1TL (VAT - 421 623 781)

Reporting of adverse reactions:

UK: Please continue to report suspected side effects to the MHRA through the Yellow Card Scheme. Please report all suspected side effects that are serious or result in harm. Serious reactions are those that are fatal, life-threatening, disabling or incapacitating, those that cause a congenital abnormality or result in hospitalisation, and those that are considered medically significant for any other reason. It is easiest and quickest to report side effects online via the Yellow Card website – https://yellowcard.mhra.gov.uk/ or via the Yellow Card app available from the Apple App Store or Google Play Store. Alternatively, prepaid Yellow Cards for reporting are available by writing to FREEPOST YELLOW CARD (no other address details necessary); by emailing yellowcard@mhra.gov.uk; at the back of the British National Formulary (BNF); by telephoning the Commission on Human Medicines (CHM) free phone line: 0800-731-6789; or by downloading and printing a form from the Yellow Card website.

Ireland: Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.

Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system HPRA Pharmacovigilance, Website: www.hpra.ie.

Adverse reactions/events should also be reported to the marketing authorisation holder at email address: CPMS@Viatris.com

Restricted access

The website you are trying to access is designed for healthcare professionals only - the content is not designed for the general public.

Are you a healthcare professional based in UK or Ireland?

YES
NO

hcp popup title

Viatris Connect is an online platform for UK health Professionals.

Across the website you will find news, blogs and product information.

Register to Viatris Connect today

Please note that the website contains promotional and non-promotional material including educational content and resources to help you and your patients.

REGISTER NOW